2021 ACMT Annual Scientific Meeting Abstracts—Virtual
Total Page:16
File Type:pdf, Size:1020Kb
Journal of Medical Toxicology https://doi.org/10.1007/s13181-021-00832-9 ANNUAL MEETING ABSTRACTS 2021 ACMT Annual Scientific Meeting Abstracts—Virtual Abstract: These are the abstracts of the 2021 American College of 001. Gender-Based Production of N-Acetyl-P-Benzoquinone Imine Medical Toxicology (ACMT) Annual Scientific Meeting. Included here Protein Adduct Formation With Therapeutic Acetaminophen are 178 abstracts that will be presented in April 2021, including research Administration studies from around the globe and the ToxIC collaboration, clinically significant case reports describing toxicologic phenomena, and encore Brandon J Sonn1, Kennon J Heard1,2, Susan M Heard2,Angelo research presentations from other scientific meetings. D'Alessandro1, Kate M Reynolds2, Richard C Dart2, Barry H Rumack1,2,AndrewAMonte1,2 Keywords: Abstracts - Annual Scientific Meeting - Toxicology 1University of Colorado Denver, Aurora, Colorado, USA. 2Rocky Investigators Consortium - Medical Toxicology Foundation Mountain Poison and Drug Center, Denver, Colorado, USA Correspondence: American College of Medical Toxicology (ACMT) Background: Acetaminophen (APAP)-associated transaminase elevation, 10645 N. Tatum Blvd Phoenix, AZ; [email protected] induced by N-acetyl-p-benzoquinone imine (NAPQI) protein adduction, re- mains a global concern. Distinct from known genetic, physiologic, and dos- Introduction: The American College of Medical Toxicology (ACMT) age associations dictating severity of hepatic injury, no known factors predict received 188 eligible research abstracts for consideration for presentation an absence of NAPQI protein adduct formation at therapeutic APAP dosing. at the 2021 Annual Scientific Meeting (ASM), including 85 research Hypothesis: Gender-based physiologies are predictive of APAP-induced studies and 103 case reports. Each abstract was reviewed in a blinded protein adduct formation at therapeutic doses. fashion by at least three Research Committee members. Each abstract Methods: This retrospective study is interrogating serum samples collect- was independently scored based on the clinical question, data source, ed for a prior study investigating fluctuations of alanine aminotransferase analytic method, results/conclusion, and clarity of presentation. A total (ALT) over time with 4 grams daily APAP dosing for ≥ 16 days in of 178 abstracts were accepted. This work would not be possible without subjects from Denver, Colorado. Subjects were grouped by NAPQI ad- the hard work and diligence of our abstract reviewers: Justin Arnold, Katie duct formation (n = 184) vs no adducts (n = 20). Samples were run on Boyle, Jeffrey Brent, Keith Burkhart, Jennifer Carey, Stephanie Carreiro, ultra-high performance liquid chromatography mass spectrometry from James Chenowth, Neeraj Chhabra, Jon Cole, Nick Connors, Fiona days 0, 7, 16, and 31. Significant metabolite expressions were identified Garlich, Spender Greene, Rob Hendrickson, Michelle Hieger, David using t-tests with false discovery rate correction (FDR), partial least Juurlink, Louise Kao, Kenneth Katz, Russ Kerns, Andrew King, Kathy squares discriminant, and ANOVA simultaneous comparison analyses. Kopec, JoAn Laes, Eric Lavonas, Michael Levine, David Liss, Kevin Demographic and clinical data were explored using t-tests with FDR (age, Maskell, William Meggs, Andrew Monte, Elissa Moore, Babak weight, BMI, ALT) and chi-square (gender, ethnicity, race) analyses. Mostafazadeh, Mark Mycyk, Mark Neavyn, Travis Olives, Patricia Results: In pre-treatment samples, relative quantitation caprylic acid was Rosen, Evan Schwarz, Samuel Stellpflug, Mark Su, Manoj Tyagi, expressed nine-fold higher and 6-carboxyhexanoate was expressed three- Shawn Varney, Steven Walsh, Richard Wang, Sage Wiener, Brandon fold lower in subjects who did not develop adducts. Lactate had greater Wills, and Luke Yip. We would also like to thank the Fellows who par- expression in the no adducts group (p = NS). Using absolute quantitation, ticipated in the inaugural review mentorship program: Vincent Calleo, glutathione was expressed 2.6-fold greater among no adduct subjects. Richard Chen, Joseph Kennedy, Jacob Lebin, and Christopher Meaden. Odds of men developing NAPQI protein adducts at therapeutic APAP Equally significant is the contribution of the ACMT staff (Adrienne dosing are 5.91 times lower than women (95% CI=2.3–14.9; p = 0.0001). Dunavin and Sandra Kirilovic) who led the process. Congratulations to Conclusion: Multiple metabolites were significantly expressed within the all the contributors whose work will be presented in April. no adduct group with known greater expression in males, such as lactate. Additionally, metabolites were identified unique to adduct development We look forward to seeing you there. independent of gender such as caprylic acid. At therapeutic APAP dosing, males are less likely to develop NAPQI protein adducts. Further research Christine Murphy, MD, FACMT, Abstract Review Chair; Peter Chai, into lipid biosynthesis and metabolism may provide further insight into MD, FACMT, Abstract Review Co-Chair; Maryann Amirshahi, physiology associated with NAPQI production. PharmD, MD, MPH, PhD, FACMT, Chair, ACMT Research Committee 002. Platelet Mitochondrial Dysfunction in Acute Acetaminophen Toxicity and with 4-Methylpyrazole Treatment 2021 ACMT Annual Scientific Meeting Abstracts—Virtual Carolyn Fox, Michael Ekaney, Michael Runyon, Iain H McKillop, Christine Murphy Day 1: Platforms, Abstracts 001–004 Atrium Health's Carolinas Medical Center, Charlotte, NC, USA J. Med. Toxicol. Background: Clinical and experimental data suggest administration of 4- Results: Injection of 500 mg/kg APAP led to significantly changed methylpyrazole (4-MP) and N-acetylcysteine in severe acetaminophen POC within 12 hours versus both control and 300 mg/kg APAP −7 (APAP) overdoses may improve morbidity and mortality. In the clinical (−2.19 ± 0.45 × 10 μgO2/min/platelet [500 mg-APAP] versus −8 setting, rapidly determining the degree of hepatic damage following −5.52 ± 1.73 × 10 μgO2/min/platelet [Control] and −7.22 ± 0.70 −8 APAP overdose remains challenging. ×10 μgO2/min/platelet [300 mg-APAP]; P < 0.05, 500 mg-APAP Hypothesis: Acetaminophen toxicity is ameliorated by 4-MP in an ex- versus Control and 300 mg-APAP), effects that were maintained at perimental model of APAP-toxicity in vivo, effects that are detectable by 24 hours. Administration of 4-MP did not significantly affect POC in changes in circulating platelet mitochondrial function assessed by control or 300 mg/kg-APAP mice. Conversely, in mice receiving 500 platelet-oxygen consumption (POC). mg/kg-APAP+4-MP, POC changed at both 12 hours (−2.19 ± 0.45 × −7 −7 Methods: Male C57Bl/6 mice (8–12 weeks old) were randomized to 10 μgO2/min/platelet [500 mg-APAP] versus −1.10 ± 0.15 × 10 receive APAP (500 or 300 mg/kg) or vehicle (0.9% [w/v] sodium chlo- μgO2/min/platelet [500 mg-APAP+4-MP]) and 24 hours (−2.22 −7 ride) intraperitoneally (ip) followed by either 4-MP treatment (50 mg/kg) ±0.49 × 10 μgO2/min/platelet [500 mg-APAP] versus −0.81 ± −7 or vehicle ip injection 90 minutes after APAP administration. Mice were 0.12 × 10 μgO2/min/platelet [500 mg-APAP+4-MP]). POC of euthanized 0 (control), 12, or 24 hours after APAP administration, and mice treated with 500 mg/kg-APAP+4-MP were not significantly platelets from cardiac blood were isolated and counted. Using a closed different from time-matched vehicle and vehicle+4MP groups. system to measure POC, mitochondrial function was determined as a ratio Conclusion: Platelet mitochondrial function can be used as an early bio- of total oxygen consumption to platelet number. Differences between marker of acute APAP toxicity, and 4-MP treatment may mitigate the groups at each time point were evaluated by analysis of variance. harmful effects of APAP on platelet mitochondrial function. This research was supported by a 2020 Medical Toxicology Foundation Innovative Research and Teaching Award. 003. Late Hemotoxicity following North American Rattlesnake venom for rattlesnake envenomation. Cases were excluded for Envenomation Treated with Crotalidae Immune F(ab’)2 (Equine) incomplete data and if less than one set of follow-up laboratory Antivenom (Anavip®) values was obtained. Data collected included demographics, en- venomation characteristics, laboratory values, and treatment ad- Meghan B Spyres1,2, Gabriel Padilla3, Richard D Gerkin1,2,Anne- ministered. Statistics: t-test and Fisher’s exact test. Hemotoxicity Michelle Ruha1,2, On Behalf of the ToxIC Investigators Consortium was defined as platelets <120 K/mm3 or fibrinogen < 170 mg/dL; (ToxIC) hemotoxicity was considered late on follow-up if values met 1Banner University Medical Center Phoenix, Phoenix, AZ, USA. threshold and were decreased from discharge value. 2University of Arizona College of Medicine Phoenix, Phoenix, AZ, Results: One hundred thirteen rattlesnake bites receiving antivenom were USA. 3University of Southern California Keck Medical School, Los reported to the NASBR in 2019, 111 were included. Twenty-seven received Angeles, CA, USA Anavip® alone, 50 received Crofab® alone, and 34 received both antivenoms. Baseline patient and envenomation characteristics were similar Background: Late hemotoxicity is common following rattlesnake en- between the groups. For single antivenom cases, Anavip® cases received venomation treated with Fab antivenom (CroFab®). Clinical trials more vials than Crofab® cases (17 vs. 11; p < 0.001), but discrete dosing showed Anavip® to be superior